Beating Infections through Research and Development Act of 2007

To provide incentives for pharmaceutical companies, biotechnology companies, and medical device companies to invest in research and development with respect to antibiotic drugs, antivirals, diagnostic tests, and vaccines that may be used to identify, treat, or prevent serious and life-threatening infectious diseases.

3/13/2007--Introduced.
Beating Infections through Research and Development Act of 2007 - Sets forth circumstances under which the term of a patent may be extended for qualified infectious disease products.
Requires the Secretary of Health and Human Services to designate qualified infectious disease products as fast-track products for approval.
Amends the Public Health Service Act to require the Director of the National Institute of Allergy and Infectious Diseases to expand and intensify efforts to assist small manufacturers to conduct end-stage clinical trials on qualified infectious disease products.
Amends the Internal Revenue Code to establish an infectious disease research credit and a qualified infectious disease products manufacturing facilities investment credit.
Establishes the Commission on Infectious Diseases Product Development to identify drug-resistant infectious pathogens that are a significant threat to public health and make recommendations to the Secretary on how best to address such pathogens.
Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary, acting through the Commissioner of Food and Drugs, to issue guidelines for the conduct of clinical trials with respect to antibiotic drugs.


... morehide bill summarySee Full Bill Text

Sponsor

• Rep. Brian Baird [D, WA-3]
• and 4 Co-Sponsors
  • Rep. John Carter [R, TX-31]
  • Rep. Barbara Cubin [R, WY-0]
  • Rep. Michael Ferguson [R, NJ-7]
  • Rep. Jim Matheson [D, UT-2]
  close

Committees

• House Judiciary
• 4 more
  • House Energy and Commerce
  • House Energy and Commerce
  • House Judiciary
  • House Ways and Means
  close

Amendments

This bill has no amendments.

Amendments to H.R.1496

Number	Status	Purpose

Bill Status

Make a Bill Status Widget (Close help)

OpenCongress widgets allow you to display information about bills and issue areas on your own website or blog. First, select which bill or issue you want to track, then customize the appearance of the panel, and finally paste a simple chunk of HTML into your site. Now your community will have an easy, up-to-date way to track the status of important bills and issues in Congress.

Introduced		Voted on by House		Voted on by Senate		Considered By President		Bill Becomes Law
March 13, 2007

Show All Actions (7 actions)Hide Actions

All Bill Actions

• Apr 20, 2007: Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
• Mar 14, 2007: Referred to the Subcommittee on Health.
• Mar 13, 2007: Referred to House Ways and Means
• Mar 13, 2007: Referred to House Judiciary
• Mar 13, 2007: Referred to House Energy and Commerce
• Mar 13, 2007: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• Introduced on Mar 13, 2007.

---

Related Issue Areas:

• Medicine
• Administrative procedure
• Antibiotics
• Biotechnology
• 36 more
• Business
• Clinical trials
• Communicable diseases
• Congressional reporting requirements
• Department of Health and Human Services
• Drug approvals
• Drug industry
• Drug resistance in microorganisms
• Executive departments
• Executive reorganization
• Federal advisory bodies
• Food and Drug Administration (FDA)
• Government information
• Government paperwork
• Health policy
• Income tax
• Influenza
• Intellectual property
• Investment tax credit
• Law
• Medical care
• Medical tests
• Patents
• Pharmaceutical research
• Public health
• Research and development
• Research and development tax credit
• Science policy
• Small business
• State and local government
• State laws
• Surveys
• Tax administration
• Taxation
• Technology
• Vaccines

Data from the Congressional Research Service

Show More User Statistics... Hide User Statistics

In the News

We are not currently finding any news articles on this topic using our daily automated search of Google News. However, if you know of a relevant news article to display here, OpenCongress site editors have the ability to add it manually. Simply e-mail us the web address of this page and the web address of your suggested news article: We'll post relevant links as quickly as possible. Also, if this topic is important to you, you could write a letter to the editor -- if a news article refers this specific topic by name, a link to that news article is likely to appear here soon.

Blog Coverage

March 12, 2007 HR 1496, To provide incentives for pharmaceutical companies ...

HR 1496 would provide incentives for pharmaceutical companies, biotechnology companies, and medical device companies to invest in research and development with respect to antibiotic drugs, antivirals, diagnostic tests, and vaccines that ...

Was this article useful? Yes or No

Source: WashingtonWatch.com - Welcome to WashingtonWatc...

Did you find this article useful? Your opinion counts - together, we're finding the very best news and blog coverage about Congress available on the web.

See most useful blog posts

Information made available by: